Get the Stockscreener App
12.22
5.25%
0.61
After Hours:
12.36
0.14
+1.15%
Capricor Therapeutics Inc Stock (CAPR) Latest News
Earnings call transcript: Capricor Q4 2024 beats EPS forecast, stock up - Investing.com India
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Capricor Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Capricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of - GuruFocus.com
Capricor Therapeutics Q4 Loss Widens, Revenue Decreases -March 19, 2025 at 04:39 pm EDT - Marketscreener.com
Capricor: Q4 Earnings Snapshot - Danbury News Times
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com - Investing.com UK
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership - Yahoo Finance
Capricor Therapeutics announces long-term data from HOPE-2 OLE study - Yahoo Finance
H.C. Wainwright maintains Capricor stock Buy rating and $77 target By Investing.com - Investing.com UK
Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
CAPRICOR THERAPEUTICS Earnings Preview: Recent $CAPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating - GlobeNewswire
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy - Marketscreener.com
Capricor reports promising DMD treatment results By Investing.com - Investing.com Australia
Breakthrough: New DMD Drug Cuts Disease Progression in Half Over 3 Years - StockTitan
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor touts long-term efficacy of DMD therapy ahead of FDA application - MSN
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - Armenian Reporter
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL
Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK
Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan
Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq
Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - Lelezard
Capricor's DMD Treatment Receives FDA Priority Review Status - StockTitan
Rhumbline Advisers Has $636,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Capricor Therapeutics to Provide Corporate Update and Participate in Investor Meetings at Leerink’s Global Healthcare Conference 2025 - Nasdaq
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire
Can Capricor's DMD Treatment Breakthrough Change Rare Disease Treatment? Key Updates Coming - StockTitan
New York State Common Retirement Fund Raises Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory - Insider Monkey
Capricor Therapeutics call volume above normal and directionally bullish - TipRanks
Capricor jumps on FDA priority review for lead drug - MSN
How To Trade (CAPR) - Stock Traders Daily
H.C. Wainwright maintains Buy on Capricor stock with $77 target By Investing.com - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Given “Buy” Rating at HC Wainwright - Defense World
Traders Buy Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy - Asianet Newsable
Capricor: Further Value Unlocked With Priority Review Of Deramiocel (NASDAQ:CAPR) - Seeking Alpha
CAPR underperforms with a -11.12 decrease in share price - US Post News
Capricor Therapeutics Shares Rise on FDA Priority Review -March 04, 2025 at 10:42 am EST - Marketscreener.com
Capricor, Wave Life Sciences, EVgo - TradingView
Capricor Therapeutics stock rises on FDA priority review By Investing.com - Investing.com Canada
Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Capricor Therapeutics’ Deramiocel Receives FDA Priority Review - TipRanks
Capricor Therapeutics Announces FDA Acceptance and Priority - GlobeNewswire
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy - The Manila Times
Capricor stock rises as FDA reviews DMD drug (CAPR:NASDAQ) - Seeking Alpha
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):